What should I do if I become resistant to tremelimumab?

Tremelimumab (tremelimumab)is approved by the U.S. Food and Drug Administration (FDA) to treat patients with unresectable hepatocellular carcinoma (liver cancer) and non-small cell lung cancer that has spread to other parts of the body and does not have abnormal EGFR or ALK genes. In this case, the patient receives tremelimumab in combination with imfinzi.

The safety and effectiveness of temsitumumab in patients <18 years of age have not been established Immune-mediated pneumonitis, colitis, or diarrhea (cytomegalovirus (CMV) infection) may occur in patients treated with temsitumumab in combination with durvalumab. , Hepatitis, adrenal insufficiency, hypophysitis/hypopituitarism, thyroiditis, hyperthyroidism, hypothyroidism, type 1 diabetes, immune-mediated nephritis, rash or dermatitis, pancreatitis. Depending on severity, withhold or permanently discontinue coadministration of temselimumab with durvalumab. However, everyone’s physique is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

Tesetumumab is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been launched in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.